These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9250565)

  • 41. 'Double hit' from streptococcal pneumonia and hypersensitivity pneumonitis associated with anagrelide.
    Spencer EM; Lawrence DS
    Clin Lab Haematol; 2006 Feb; 28(1):63-5. PubMed ID: 16430463
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia.
    Kanakura Y; Shirasugi Y; Yamaguchi H; Koike M; Chou T; Okamoto S; Achenbach H; Wu J; Nakaseko C
    Int J Hematol; 2018 Nov; 108(5):491-498. PubMed ID: 30121892
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anagrelide: a novel agent for the treatment of myeloproliferative disorders.
    Pescatore SL; Lindley C
    Expert Opin Pharmacother; 2000 Mar; 1(3):537-46. PubMed ID: 11249536
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Thrombocytosis in chronic myelogenous leukemia (CML) controlled by interferon alpha (IFN-alpha)].
    Koike G; Otsuka T; Shibuya T; Niho Y
    Rinsho Ketsueki; 1989 Mar; 30(3):400-3. PubMed ID: 2769964
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic plateletpheresis in a case of symptomatic thrombocytosis in chronic myeloid leukemia.
    Thakral B; Saluja K; Malhotra P; Sharma RR; Marwaha N; Varma S
    Ther Apher Dial; 2004 Dec; 8(6):497-9. PubMed ID: 15663550
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hydroxyurea and periodicity in myeloproliferative disease.
    Bennett M; Grunwald AJ
    Eur J Haematol; 2001 May; 66(5):317-23. PubMed ID: 11422411
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Platelet-lowering therapy with anagrelide as an adjuvant therapy for treatment of primary pulmonary neoplasm-associated extreme thrombocytosis.
    Chen YG; Lin CS; Shen CH; Chian CF
    Jpn J Clin Oncol; 2012 Aug; 42(8):761-3. PubMed ID: 22689919
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.
    Litam PP; Landaw SA; Zamkoff KW
    Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Platelet Anti-Aggregator Drowns the Heart.
    Siddiqui MU; Siddiqui MD; Hameed S; Naeem Z; Siddiqui M
    S D Med; 2021 Nov; 74(11):502-505. PubMed ID: 35008135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Anagrelide--a new drug to reduce platelets in myeloproliferative diseases].
    Bennett M
    Harefuah; 1999 May; 136(9):717-20. PubMed ID: 10955097
    [No Abstract]   [Full Text] [Related]  

  • 52. Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation.
    Lane WJ; Hattori K; Dias S; Peerschke EI; Moore MA; Blanset DL; Lang PC; Petrone M; Rafii S
    Exp Hematol; 2001 Dec; 29(12):1417-24. PubMed ID: 11750100
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of essential thrombocythemia with anagrelide.
    Silverstein MN; Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):23-5. PubMed ID: 9930554
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-output heart failure associated with anagrelide therapy for essential thrombocytosis.
    Engel PJ; Johnson H; Baughman RP; Richards AI
    Ann Intern Med; 2005 Aug; 143(4):311-3. PubMed ID: 16103481
    [No Abstract]   [Full Text] [Related]  

  • 56. Platelet apheresis for extreme thrombocytosis in an 11-year-old girl with CML.
    McCarthy LJ; Graves VL; Eigen H; McGuire WA
    Transfus Med; 1991 Sep; 1(3):187-9. PubMed ID: 9259847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute myocardial infarction and anagrelide.
    Schaaf M; Sibellas F
    Int J Cardiol; 2013 Sep; 168(2):e50-2. PubMed ID: 23871356
    [No Abstract]   [Full Text] [Related]  

  • 58. A Case of acute Myocardial Infarction in a Patient with Essential Thrombocythaemia Treated with Anagrelide.
    Yetiskul E; Nisar A; Khan S; Qaqish F; Khan D; Bershadskiy A
    Eur J Case Rep Intern Med; 2024; 11(3):004340. PubMed ID: 38455691
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cecal cancer with essential thrombocythemia treated by laparoscopic ileocecal resection: a case report.
    Hiyoshi M; Nozawa H; Inada K; Koseki T; Nasu K; Seyama Y; Wada I; Murono K; Emoto S; Kaneko M; Sasaki K; Shuno Y; Nishikawa T; Tanaka T; Hata K; Kawai K; Maeshiro T; Miyamoto S; Ishihara S
    Surg Case Rep; 2019 Jun; 5(1):101. PubMed ID: 31227949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anagrelide-induced cardiomyopathy.
    James CW
    Pharmacotherapy; 2000 Oct; 20(10):1224-7. PubMed ID: 11034048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.